NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson’s Disease in Patients of European Descent

Wai Yan Yau1* FRACP, Roisin Sullivan1 MSc, Clarissa Rocca1 MSc, Elisa Cali1 MD, Jana Vandrovova1 PhD, Nicholas W Wood2,3 FRCP, PhD, Henry Houlden1,3 FRCP, PhD

1 Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology, London, United Kingdom
2 Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom
3 Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom

*Both authors contribute equally to this study

Page count: 6
Word count: 336
Number of figure: 1
Out of 1011 sporadic Parkinson’s Disease (PD) patients of Chinese ethnicity, Shi et al. identified 11 patients with intermediate-length GGC repeat expansions (41-64 repeats) in NOTCH2NLC\(^1\). Interestingly, the skin samples in 2 of these patients demonstrated phospho-alpha-synuclein deposition rather than the typical inclusion bodies of neuronal intranuclear inclusion disease. We aimed to validate the association between this intermediate-length repeat expansions and PD in an ethnically different cohort.

We estimated the NOTCH2NLC GGC allele sizes in 825 PD patients of European descent—in whom pathogenic repeat expansions were previously excluded\(^2\)—by amplifying the genomic DNA region containing the repeat using polymerase chain reaction primers specific for NOTCH2NLC\(^3\). The genomic DNA of all patients were from the National Institute of Neurological Disorders and Stroke Human Genetics and Cell Line Repository, United States. The study was approved by the joint ethics committee of University College London Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, United Kingdom (UCL: 19/LO/1796).

In our PD cohort, we did not identify any patient with intermediate-length repeat expansions. The estimated repeat sizes ranged from 10 to 38 in our patients (Figure 1). Our study is limited by a lack of a control group. In addition, use of long-read sequencing may also achieve better estimates of GGC repeat sizes and ascertain the presence of repeat interruption. However, these factors should not impact on the result of this study.
Despite of the negative screen in our cohort, another case-control study in 1000 Chinese sporadic PD patients identified that 1% of them carried intermediate-length GGC repeat expansions in \textit{NOTCH2NLC}$^4$. Furthermore, gray-zone GGC alleles (41-54 repeats) at \textit{FMR1}—another neurodegenerative disease caused by polyglycine expansions—are also associated with increased risk of PD in women$^5$. Shi et al. posited \textit{NOTCH2NLC} protein upregulation and autophagy dysfunction as the potential pathomechanism in PD patients with intermediate-length GGC repeat expansions$^1$. Therefore, the role of intermediate-length GGC in \textit{NOTCH2NLC} as a genetic risk factor of PD remains to be confirmed and requires further studies with larger longitudinal clinic-pathological cohorts.

\textbf{Acknowledgement}

This study used a Parkinson’s disease panel from the NINDS Repository. The submitters who contributed samples are acknowledged in detailed descriptions of each panel: NDPT083, NDPT085, NDPT087, NDPT088, NDPT089, NDPT101, NDPT102, NDPT104, NDPT105. We are grateful to Professor Shoji Tsuji from Department of Neurology of the University of Tokyo providing us with genomic DNA of the positive control. W.Y.Y. receives a PhD studentship from Ataxia UK and Rosetrees Trust and funding from a Nicholas Blair MDSANZ travelling fellowship. R.S. receives funding from MRC. We are grateful to the Medical Research Council (MRC), The Wellcome Trust Synaptopathies award, MRC Centre grant (G0601943), Ataxia UK, The Rosetrees Trust, Brain Research UK, UCL ODA/LMIC award, The MSA Trust, MDUK, The Muscular Dystrophy Association (MDA). This research was
also supported by the UCL/UCLH National Institute for Health Research University
College London Hospitals Biomedical Research Centre.

Author contributions
WYY, RS, NWW and HH contributed to conception and design of the study; WYY,
RS, CR, EC and JV contributed to the acquisition and analysis of data; WYY and RS
contributed to drafting the text and preparing the figures.

Potential conflicts of interest
The authors declare no competing interests.

Data availability
The data supporting the findings of this study are available from the corresponding
author upon reasonable request.
References


Figure legend

Figure 1. Distribution of the GGC repeat length of NOTCH2NLC in the 825 Parkinson’s disease patients of European descent.
Figure 1. Distribution of the GGC repeat length of NOTCH2NL in the 825 white patients with Parkinson’s Disease.

This article is protected by copyright. All rights reserved.